Xuzhishi Technology Secures Tens of Millions in Series A Funding to Accelerate Global Leadership in AI-Driven Brain Science

VCBeat has exclusively learned that the globally leading AI healthcare and brain science companyHangzhou Xuzhishi Technology Co., Ltd. (hereinafter referred to as “Xuzhishi Technology”), announcing the completion ofTop Star CapitalLeading a tens-of-millions-yuan Series A financing round.

The proceeds from this financing round will be primarily used to accelerate the R&D of medical products in China and overseas, build consumer-facing and expert market teams, further solidify Xuzhishi Technology’s leading position in digital therapeutics for brain disorders in China, and explore more innovative business models to deliver superior products and services to users.

Xuzhishi Technology is the first company in China to apply digital technologies to the treatment of various brain disorders, and has been recognized as a “Specialized, Refined, Differential, and Innovative” (SRDI) enterprise as well as a High-Tech Enterprise. The company brings together top-tier talent from both domestic and international arenas across multiple cutting-edge fields, including neuroscience, artificial intelligence, medicine, bioengineering, and virtual reality. This diverse team not only possesses profound academic expertise but also rich practical experience and innovative thinking, dedicated to exploring the boundaries between the virtual and the real and promoting the deep integration of technology and the humanities. Notably, returnees account for 30% of the company’s workforce, underscoring Xuzhishi Technology’s strong emphasis on global perspectives and cross-cultural communication, while enabling the team to fully absorb the world’s most advanced scientific achievements and technological trends, thereby injecting continuous innovative vitality into the company’s R&D projects.

Guided by the therapeutic needs of specialized medical departments, Xuzhishi Technology has developed the industry’s first VR-based therapeutic product for cognitive impairment, securing China’s first medical device registration certificate in this field.

After eight years of dedicated development, the company has established a comprehensive product portfolio spanning psychiatry, neurology, pediatrics, rehabilitation, and psychology. Its solutions have been deployed in hundreds of hospitals across more than 20 provinces in China, serving over one million patient visits. Furthermore, the company has obtained EU and Southeast Asian certifications, with its products exported to overseas markets.

Xuzhishi Technology Products

In terms of technological innovation, Xuzhishi Technology has broken through the limitations of traditional gesture control by leveraging its breakthroughs in visual spatial computing technology. This achievement fills a gap in the field of brain disease treatment both domestically and internationally, injecting strong momentum into the efficient development of life sciences, brain science, medical health, and the elderly care industry. Furthermore, by deeply integrating VR (Virtual Reality), MXR (Mixed Reality/Spatial Computing Units), and XTDX digital therapeutics, the system utilizes AI-driven automated services to generate personalized rehabilitation pathways based on individual data across various medical and academic research scenarios. It also adjusts training scripts in real-time under computer-monitored environments to optimize therapeutic outcomes. This technology not only supports clinical departments and medical institutions in areas such as brain disease screening, assisted diagnosis, and non-pharmacological treatments but also meets the needs of national defense and social governance, providing target populations with high-standard treatment experiences that comply with medical regulations.

Eight Years of Forging Ahead, Setting Sail Anew Today. With the Injection of Capital in This Round,The founding team of Xuzhishi Technology stated: “Over the past few years, we have dedicated ourselves to the medical field, pouring our full passion and expertise into the treatment and management of chronic brain disorders. This round of capital injection is not only an affirmation of our achievements in research and intervention for chronic brain diseases but also a strong vote of confidence in our future potential. We will remain true to our original mission, leveraging advanced technologies such as virtual reality and artificial intelligence to improve patients’ quality of life and accelerate the diagnosis and treatment processes. Moving forward, we will continue to combine precision medicine with personalized rehabilitation programs, bringing unprecedented hope and transformation to patients suffering from various chronic brain disorders.”

Hereby, on behalf of Xuzhishi Technology, we extend our sincere gratitude to every investor for their trust and support. We will take this as our impetus to set sail and continue moving steadfastly forward in exploring comprehensive diagnostic and therapeutic solutions for chronic brain diseases, striving to become a leader in this field and contributing our strength to human health and well-being. We also hope that more medical and technical experts will join our team.

Professor Ma Ning, Chief Scientist of Xuzhishi TechnologyIt stated: “Leveraging advanced brain science research and multimodal biomarker analysis, the company precisely identifies therapeutic targets. By monitoring physiological signals in real time—including electroencephalography (EEG), electrooculography (EOG), electrocardiography (ECG), and electrodermal activity (EDA/GSR)—our system dynamically adjusts rehabilitation protocols to deliver a highly personalized treatment experience. The system integrates posture recognition and emotion recognition technologies, using cameras to capture patients’ body movements and facial expressions, automatically identifying emotional states and postures to provide a more natural and human-centered interactive experience.”

We have developed an advanced intelligent decision support system leveraging large language models (such as GPT) to analyze vast amounts of clinical data, identify the most effective treatment strategies, and enhance therapeutic efficacy and efficiency. Meanwhile, we employ quantum encryption and blockchain technology to ensure data privacy and trustworthiness, thereby safeguarding patient information security. Through these core technological barriers, we not only provide patients with more effective rehabilitation treatments but also create substantial value for our partners, lead industry development, and contribute to global healthcare. Finally, we warmly welcome like-minded experts to join us in shaping a new blueprint for brain medicine.”

Investor in this round: Top Star CapitalXuzhishi Technology is a leading enterprise in China at the intersection of AI and brain science. Leveraging extensive brain science data and clinical feedback accumulated over many years, the company has developed advanced AI algorithms and large models, securing a distinct competitive advantage. Its strong user reputation and widespread product application fully demonstrate the profound technical expertise and practical experience the company has amassed over the past decade in fields such as brain science, neuropsychiatry, applied large language models, and artificial intelligence (AI). The company’s team is young and highly motivated. We expect Xuzhishi Technology to maintain its industry leadership through sustained R&D investment, further strengthen its product portfolio and technological moat, and explore more diversified business models. We will also provide momentum for the company’s development, grow alongside it, contribute to the advancement of brain science, and deliver innovative and effective med-tech cross-disciplinary solutions to a broad patient population.

Co-investor in this round: AIalpha Ventures“The product and technological expertise that Xuzhishi Technology has accumulated in brain science and AI-driven healthcare have left a deep impression on us. Over the past nine years, Xuzhishi Technology has fully embraced an industry-deepening strategy characterized by ‘one meter wide, one hundred meters deep’ in the fields of neurology, psychiatry, and rehabilitation medicine. We believe that with the continued advancement of next-generation AI technologies and brain science, Xuzhishi Technology has the potential to become a leading global player in the AI-powered digital healthcare industry. We look forward to collaborating with Xuzhishi Technology to help hospitals and patients around the world address their challenges.”

Existing Shareholder: Liuheqiao Venture Capital“It is evident that Hangzhou Xuzhishi Technology Co., Ltd. has demonstrated remarkable innovation and industry leadership in the cutting-edge field of AI + Brain Science. Throughout its development, Xuzhishi Technology has accumulated substantial data resources through years of extensive collection of brain science data and meticulous organization of clinical feedback. Leveraging these valuable assets, the company has successfully developed industry-leading AI algorithms and large language models, granting it a significant competitive advantage. The breadth of product applications and positive user feedback fully reflect Xuzhishi Technology’s solid technical foundation and rich practical experience in fields such as brain science, neuropsychiatry, applied large models, and artificial intelligence. The team at Xuzhishi Technology is vibrant and youthful, embodying an entrepreneurial spirit and efficient execution that inspire great confidence in the company’s future prospects. We firmly believe that by maintaining continuous R&D investment and adhering to an innovation-driven development philosophy, Xuzhishi Technology will further consolidate its leading position in the industry. In terms of business expansion, the company will not only enrich its product portfolio but also deepen its technological moat, thereby exploring more diversified business models.””

Top Star Capital was established in 2018. Its founding team hails from China’s top investment institutions and leading industry enterprises. The core members possess a broad international perspective, extensive investment experience, and deep industry resources, having participated in the investment and management of over 100 companies, nearly 20 of which have successfully listed on major global capital markets. Since its inception, Top Star Capital has adhered to its mission of “Investment Changes Lives,” firmly believing that “Technology Makes Life Better.” It is committed to long-term, in-depth early-stage and growth-stage investments in the fields of life and health, technological intelligent manufacturing, and new lifestyles. The primary limited partners of Top Star Capital’s managed funds include renowned market-oriented fund-of-funds, listed companies, industry leaders, and government guidance funds.

AIalpha Ventures was co-founded by Danyu Capital alongside numerous executives from major technology firms, entrepreneurs, and investors. It is dedicated to advancing the application and empowerment of a new wave of artificial intelligence technologies across key industries. Recently, AIalpha Ventures has focused its investment opportunities on AI verticals such as AI healthcare, smart elderly care, and global expansion.